Fradafiban is used in medical research as a potential antiplatelet agent targeting the GPIIb/IIIa receptor on platelets. It inhibits platelet aggregation, helping to prevent blood clot formation. This compound shows promise in the prevention and treatment of thrombotic disorders, such as acute coronary syndromes and ischemic strokes. However, it remains in clinical development and has not been approved for widespread medical use.